Clinical trials: Patients With Major Depressive Disorder
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive Disorder, Major
Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
Developing more effective and faster acting antidepressant is of outmost clinical importance. Available antidepressant therapies have a delayed therapeutic effect.
- Trial name
- NCT02659085
- Testing
- Ketamine IV Infusion, ECT
- Where
- Sweden
- Volunteers
- 198 people
- Sponsor
- Pouya Movahed Rad
Depression, Major Depressive Disorder
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression
Depression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the…
- Trial name
- NCT00744406
- Testing
- Cognitive Behavioral Therapy, Interpersonal Therapy, Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Centre for Addiction and Mental Health
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Depression
The Early Medication Change (EMC) Trial
The EMC trial investigates for the first time prospectively whether Major Depression Disorder patients with non-improvement after 14 days of antidepressive treatment with EMC are more likely to become remitters compared to…
- Trial name
- EMC (NCT00974155)
- Testing
- Escitalopram, venlafaxine, lithium, Escitalopram, venlafaxine
- Where
- Germany
- Volunteers
- 889 people
- Sponsor
- K. Lieb
Depressive Disorder, Major
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis.
- Trial name
- NCT03207438
- Testing
- Quetiapine 50 MG Extended Release Oral Tablet, Quetiapine Fumarate XR 150-300 mg
- Volunteers
- 1,790 people
- Sponsor
- University of Saskatchewan
Major Depressive Disorder
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large…
- Trial name
- NCT05450432
- Testing
- Ketamine, Esketamine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Major Depressive Disorder
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.
- Trial name
- NCT00109044
- Testing
- Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 540 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD)
tVNS, Motivation, and Insulin Sensitivity
Disturbances in energy metabolism significantly increase the risk of developing major depressive disorder (MDD), especially in individuals with type 2 diabetes.
- Trial name
- NCT07198100
- Testing
- Transcutaneous non-invasive vagus nerve stimulation (tVNS), Oral glucose tolerance test (oGTT)
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Major Depressive Disorder
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.
- Trial name
- NCT00694304
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 535 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04533529
- Testing
- Seltorexant
- Where
- 122 sites in United States, Brazil and 9 more
- Volunteers
- 588 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Visceral Pain, Major Depressive Disorder
Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder
Ketamine is a dissociative anesthetic and powerful analgesic. At low doses, ketamine can desensitize the central pain pathway and modulate opioid receptors.
- Trial name
- NCT04847245
- Testing
- Pregabalin 75mg tid + Duloxetine, Intravenous administration of esketamine 0.125 mg/kg+Duloxetine, Intravenous administration of esketamine 0.25 mg/kg +Duloxetine
- Volunteers
- 80 people
- Sponsor
- Peking University
Depression, Major Depressive Disorder
Diet and Depression
This study is a pilot open label crossover trial to assess the feasibility and acceptability of reducing ultra- processed foods (UPF) in a personalized manner from the diets of patients with major depressive disorder who eat a…
- Conditions
- Depression, Major Depressive Disorder, Weight Gain, Obesity
- Trial name
- NCT06252701
- Testing
- Reduction of Ultra-processed foods
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
A Study of Xiongdan Wan Treating Depression
This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang Hai Mental Health Center.
- Trial name
- NCT05136365
- Testing
- Xiongdan Wan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
Long-term Study With Trazodone Once-a-Day
The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute…
- Trial name
- NCT04295941
- Testing
- TraZODone Hydrochloride 300 MG
- Where
- Bulgaria
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder, Generalized Anxiety Disorder
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
The primary objective of the study is to determine whether quetiapine extended-release in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo in treating depressive and anxiety symptoms in…
- Trial name
- NCT01971203
- Testing
- seroquel xr, CBT
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiovascular Risk, Depression, Unipolar
LIVES: Personalized Lifestyle Intervention for Patients With Depression
Persons with affective disorder have a considerably increased risk of cardiovascular disease. To a considerable extent, this is due to an unhealthy life style.
- Conditions
- Cardiovascular Risk, Depression, Unipolar, Depression, Bipolar
- Trial name
- LIVES (NCT05767073)
- Testing
- Lifestyle InterVEntion (LIVE)
- Where
- 2 sites in Netherlands
- Volunteers
- 38 people
- Sponsor
- University Medical Center Groningen
Depressive Disorder, Major
A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
The purpose of the study is to evaluate effect of JNJ-42847922 on sleep latency (latency to persistent sleep) in participants with major depressive disorder who are stably treated with selective serotonin reuptake…
- Trial name
- NCT02067299
- Testing
- JNJ-42847922
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Janssen Research & Development, LLC